Alyeska Investment Group L.P. Has $16.17 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Alyeska Investment Group L.P. lessened its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 9.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,585 shares of the company's stock after selling 21,246 shares during the period. Alyeska Investment Group L.P. owned about 0.16% of Vaxcyte worth $16,174,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Whipplewood Advisors LLC bought a new position in Vaxcyte during the fourth quarter worth about $28,000. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new position in shares of Vaxcyte during the 4th quarter worth approximately $41,000. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after acquiring an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its stake in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $0.29 during trading hours on Friday, hitting $31.16. 2,030,375 shares of the stock were exchanged, compared to its average volume of 1,309,427. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The company has a market cap of $4.02 billion, a PE ratio of -6.77 and a beta of 1.27. The company's fifty day simple moving average is $46.66 and its two-hundred day simple moving average is $74.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the company posted ($0.85) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PCVX. The Goldman Sachs Group dropped their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America decreased their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.